Cited by 491T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells

Open access

Tekguc, Murat, Wing, James Badger, Osaki, Motonao, Long, Jia, Sakaguchi, Shimon·2021·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.2023739118PMC PMC8325248

Open this paper in CoChat — free account

Abstract

Significance Immunosuppressive Tregs constitutively express CTLA-4, an immune checkpoint receptor. Addressing the role of CTLA-4 in Treg-suppressive function, we show that Treg-expressed CTLA-4, even in the absence of its cytoplasmic portion, promoted the conjugation of Tregs and antigen-presenting cells (APCs), leading to CTLA-4–dependent trogocytosis of CD80/CD86 and concomitant transfer of membrane fragments from APCs to the Treg cell surface. The depletion or blockade of CD80 by trogocytosis or solubilized CTLA-4, respectively, increased free PD-L1 by disrupting cis-CD80/PD-L1 heterodimers on APCs. Thus, Tregs can exert dual suppressive effects through the limitation of CD80/CD86 and up-regulation of free PD-L1 on APCs. Cancer immunotherapy with anti–CTLA-4 and anti–PD-1/PD-L1 blocking antibodies may enhance tumor immunity by hindering this Treg-mediated immune suppression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.2023739118

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

How regulatory T cells work
Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Self-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Self-citation
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Shevach, E. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.010 · Cited by 1,787
Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,785
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., & Sakaguchi, S. (1998) · International Immunology · doi:10.1093/intimm/10.12.1969 · Cited by 1,566
Self-citation
Regulatory T Cells and Human Disease
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041717 · Cited by 1,163
Self-citation

Show all 53 references

Sorted by citations

Items 201–300 of 491

Treg Control of CD80/CD86 Expression Mediates Immune System Homeostasis
Kim, Y., Panda, A. K., & Shevach, E. M. (2025) · European Journal of Immunology · doi:10.1002/eji.202551771 · Cited by 10
“In addition to the occupancy of CD80/CD86, CTLA-4 functions extrinsically by capturing CD80/CD86fromAPCbyaprocessoftransendocytosisultimately leading to intracellular degradation of the captured CD80/CD86 molecules and depletion of APC-delivered costimulatory signals [22–25].”
Mechanisms of tumor-associated macrophages promoting tumor immune escape
Li, S., Zhang, M., Gao, Y., Zhao, C., Liao, S., Zhao, X., Ning, Q., & Tang, S. (2025) · Carcinogenesis · doi:10.1093/carcin/bgaf023 · Cited by 11
Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer
Kang, X., Li, Y., Han, Y., Wu, M., Peng, Q., Dong, J., & Wei, J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.032 · Cited by 10
Physiological and therapeutic relevance of T cell receptor-mediated antigen trogocytosis
Martínez, N., & Alarcón, B. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100630 · Cited by 13
“Based on the above, trogocytosis implies internalizing functional and unmodified proteins from donor cells: MHC, costimulatory molecules, adhesion molecule receptors, tumor antigens, and antigenic pathogens [18].”
BackgroundInfluential
Association of immune cell traits with Parkinson’s disease: a Mendelian randomization study
Song, Z., Li, W., Han, Y., Xu, Y., Ding, H., & Wang, Y. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1340110 · Cited by 10
“In vitro studies have shown that IFN-β upregulates CD86 expression on DCs and inhibits the Th1 response via these cells (Tekguc et al., 2021).”
Background
Crosstalking with dendritic cells: a path to engineer advanced T Cell immunotherapy
Schäfer, S., Chen, K., & Ma, L. (2024) · Frontiers in Systems Biology · doi:10.3389/fsysb.2024.1372995 · Cited by 9
Dominant immune tolerance in the intestinal tract imposed by RelB-dependent migratory dendritic cells regulates protective type 2 immunity
Geiselhöringer, A.-L., Kolland, D., Patt, A. J., Hammann, L., Köhler, A., Kreft, L., Wichmann, N. O., Hils, M., Ruedl, C., Riemann, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53112-9 · Cited by 9
Extracellular Vesicle-Based Strategies for Tumor Immunotherapy
Jiramonai, L., Liang, X.-J., & Zhu, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020257 · Cited by 10
“Additionally, Tregs express the checkpoint protein cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) at high levels, which downregulates CD80 and CD86 molecules on APCs, thereby limiting T-cell-mediated immunity [94].”
Overcoming the novel glycan–lectin checkpoints in tumor microenvironments for the success of the cross-presentation-based immunotherapy
Jain, M., Jadhav, I. M., Dangat, S. V., Singuru, S., Sethi, G., Yuba, E., & Gupta, R. K. (2025) · Biomaterials Science · doi:10.1039/d4bm01732c · Cited by 9
Regulatory T cells in renal cell carcinoma: tumor-promoting mechanisms and emerging therapeutic strategies
Li, Z., Ma, J., Xu, M., Duan, Y., Huang, C., Dai, Q., & Yang, Z. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115322 · Cited by 9
Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies
Chen, Y., Chen, D., Liang, Z., Yu, H., Sun, H., Hu, Y., Jiang, P., Zhang, M., Ye, L., & Li, H. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.120 · Cited by 9
Single-Cell RNA-seq Analysis Reveals Dysregulated Cell-Cell Interactions in a Tumor Microenvironment Related to HCC Development
Liu, Z., Zhang, S., Ouyang, J., Wu, D., Chen, L., Zhou, W., & Xie, L. (2022) · Disease Markers · doi:10.1155/2022/4971621 · Cited by 9
“CTLA4 was uniquely identified with a higher degree in the HCC interaction network (Figure 5), while in HCC, CTLA4 interacted with CD86, which may participate negatively in the regulation of T cell activation and diminishment of immune response [29].”
Programmed death receptor 1 (PD‐1) ligand Fc fusion proteins reduce T‐cell proliferation in vitro independently of PD‐1
Biemond, M., Vremec, D., Gray, D. H. D., Hodgkin, P. D., & Heinzel, S. (2023) · Immunology and Cell Biology · doi:10.1111/imcb.12714 · Cited by 10
“13 27 Nevertheless, PD-L1.”
Coordinated network of T cells and antigen presenting cells regulate tolerance to foodPreprint
Rudnitsky, A., Oh, H., Talmor, J., & Kedmi, R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.11.603064 · Cited by 9
“One of the means by which Treg cells suppress the expansion of effector T cells is through the depletion of CD80/CD86 costimulatory molecules from APCs by trogocytosis 26–28 .”
Background
Immune Regulation Patterns in Response to Environmental Pollutant Chromate Exposure-Related Genetic Damage: A Cross-Sectional Study Applying Machine Learning Methods
Su, Z., Zhang, Y., Hong, S., Zhang, Q., Ji, Z., Hu, G., Zhu, X., Yuan, F., Yu, S., Wang, T., et al. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.4c00433 · Cited by 8
Single-nuclei sequencing of uterine serous carcinoma reveals racial differences in immune signaling
Foley, K. G., Adli, M., & Kim, J. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402998121 · Cited by 8
“CTLA4 is a negative regulator of T cell activation and competes with antigen - presenting cells to stimulate CD28 (30).”
Context-restricted PD-(L)1 checkpoint agonism by CTLA4-Ig therapies inhibits T cell activity
Oxley, E. P., Kershaw, N. J., Louis, C., Goodall, K. J., Garwood, M. M., Ho, S. M. J., Voo, V. T. F., Park, H.-Y., Iaria, J., Wong, L. L. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114834 · Cited by 8
Decoding the complex web: cellular and molecular interactions in the lung tumour microenvironment
Issa, B. S., Adhab, A. H., Mahdi, M. S., Kyada, A., Ganesan, S., Bhanot, D., Naidu, K. S., Kaur, S., Mansoor, A. S., Radi, U. K., et al. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2445772 · Cited by 8
“…to cD80/cD86 on APcs. this prevents proper t cell co-stimulation. in addition, tregs may suppress APcs/ctls by upregulating PD-l1 on these cells [154]. targeting tregs or their expressed and released molecules can be suggested for overcoming lung tumour resistance to different shapes of…”
TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory
Yu, H., Jin, S., Zeng, M., Yang, Z., & Wang, X. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03046-w · Cited by 8
“…studying tumour biology, however, the biological difference among patients affects the consistency and reproducibility of experimental results signi ﬁ cantly, further research and optimisation are needed to address challenges such as individual variability, and model vascular systems complexity.”
Regulatory T Cells in Invasive Breast Cancer: Prognosis, Mechanisms and Therapy
Xu, A., Ayoub, S., Zhang, H., Wu, Y., Rau, M., & Ma, X. (2025) · Cancers · doi:10.3390/cancers17193172 · Cited by 8
“Recent mechanistic insights from Tekguc et al. [52]. revealed that Treg-expressed CTLA-4 depletes CD80/CD86 through trogocytosis, releasing free PD-L1 on antigen-presenting cells, providing a novel mechanistic link between CTLA-4 and PD-L1 pathways that explains the synergistic effects of…”
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial
Wang, Z., Li, L., Huang, P., Tu, H., Zhang, X., Lei, Y., Liang, F., Huang, C., Qiu, S., Ye, Q., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00268-7 · Cited by 9
CD8+ Regulatory T Cells
Vuttaradhi, V. K., Vermelle, C. M., Choi, J. Y., Niu, L., Tang, X., Azzi, J. R., & Cantor, H. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-083024-030412 · Cited by 9
“Whether these CD8 + Foxp3 + Tregs recognize DC antigens or antigens of the activated CD4 + T cells acquired by DCs via trogocytosis is unclear (105, 106).”
Regulatory T cells in cancer and inflammation
Yang, H., Zhang, H., Xia, N., & Cheng, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02584-w · Cited by 8
“Tumor cells, CAFs, DCs, and tumor-associated macrophages (TAMs) secrete various chemokines to recruit Tregs into the TME through speci ﬁ c chemotactic axes, including CCL17/ CCL22 – CCR4, 108 CCL2 – CCR2/CCR4, 109,110 CCL1 – CCR8, 111,112 CCL5 – CCR5, 113,114 CCL28 – CCR10, 115 and CXCL12 – CXCR4.”
Influential
Rational Engineering of Islet Tolerance via Biomaterial-Mediated Immune Modulation
Klug, N., Burke, J. A., & Scott, E. A. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300527 · Cited by 8
Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs
Kannan, K., & Mohan, S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02755-9 · Cited by 8
“…ac k e d r a ndo m i za ti on a nd f o c u s e d on s i ng l e - c oun - t r y c oho r t s , w h i c h m a y li m it g e n e r a li za b ilit y G r a d e 3–4 a dv e r s e e ff ec t s o cc u rr e d [ 155 ] in Tregs, and its blockade also reduces the immunosuppressive effects mediated by Tregs [158].”
Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4+Foxp3+ Regulatory T Cell Immunosuppression
Shao, Y., Yang, W. Y., Nanayakkara, G., Saaoud, F., Issa, M. B., Xu, K., Lu, Y., Jiang, X., Mohsin, S., Wang, H., et al. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100022 · Cited by 7
“Consequently, there is increased interaction between PD-1 and PD-L1 on T cells [117,118], leading to the negative regulation of T cell function [119].”
Resveratrol promotes cholesterol efflux from dendritic cells and controls costimulation and T-cell activation in high-fat and lipopolysaccharide-driven atherosclerotic mice
Zhang, L., Wang, H., Wang, Z., Xu, J., Wang, M., Wang, W., He, Q., Yu, Y., Yuan, D., Bu, G., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1450898 · Cited by 7
“DCs can also create a microenvironment that enables naïve T cells to differentiate into effector T cells by releasing cytokines, which is also known as the “ third signal ” (55, 56).”
Self-citation
Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families
Liu, R., Jiang, X., Dong, R., Zhang, Y., Gai, C., & Peng, W. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1499663 · Cited by 7
“CTLA-4 inhibitors exert anti-tumor effects by preventing Tregs from down-regulating CD80/86 expression and depleting Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP) (78).”
Immune and Angiogenic Profiling of Mesenchymal Stem Cell Functions in a Subcutaneous Microenvironment for Allogeneic Islet Transplantation
Campa‐Carranza, J. N., Capuani, S., Joubert, A. L., Hernandez, N., Bo, T., Sauceda‐Villanueva, O. I., Conte, M., Franco, L., Farina, M., Rome, G. E., et al. (2025) · Advanced Science · doi:10.1002/advs.202411574 · Cited by 9
CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects
Wang, J., Feng, Y.-F., & Liu, J.-H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1629879 · Cited by 8
“Furthermore, combination therapy signi ﬁ cantly increases the CD8+/Treg ratio (41, 42), supports memory CD8+ T cell formation, and promotes tissue-resident memory T cells (TRMs), reinforcing long-term immune surveillance (43).”
The homeostasis and heterogeneity of regulatory T cells in sepsis
Wu, D., Zhang, H., & Miao, C. (2025) · Burns & Trauma · doi:10.1093/burnst/tkaf047 · Cited by 8
“…+ Tregs can form relatively stable immune synapses with antigen-presenting cells (APCs) and induce the upregulation of free PD-L1 on APCs, which effectively prevents naive T cell activation and causes effector T cell exhaustion and functional inhibition through dual inhibitory mechanisms [76].”
Unmasking immune checkpoint resistance in esophageal squamous cell carcinoma: Insights into the tumor microenvironment and biomarker landscape
Wang, Z., Zhang, R., Xu, Y., Yue, B., Zhang, J., & Wang, F. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i8.109489 · Cited by 7
“…helps explain why: CTLA-4 removal not only expands a progenitorlike pool of exhausted CD8 + T cells that can be rejuvenated by PD-1 blockade but also strips regulatory T cells of their ability to steal CD80/86 from antigenpresenting cells, thereby freeing additional PD-L1 for interception[31,83].”
Multimodal cell-cell communication driving CD8+ T cell dysfunction and immune evasion
Chen, L., Huang, Q., & Zhou, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1691746 · Cited by 8
“CTLA-4 not only transmits intrinsic inhibitory signals but also, on Tregs, mediates the trans-endocytosis and degradation of CD80-CD86 from the APC surface, thereby limiting co-stimulation for other T cells (43, 45).”
Skin immunity and inflammation: cellular interactions and communication
Narayanan, D., Sim, S.-L., & Kumari, S. (2025) · Clinical & Translational Immunology · doi:10.1002/cti2.70053 · Cited by 10
Oxaliplatin-artesunate conjugate intensifies suppression on colorectal cancer by boosting antitumor immunity
Tan, Y., Yang, T., Jiang, S., Li, S., Cai, L., Wang, Y., Guo, Z., & Wang, X. M. (2026) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2026.113212 · Cited by 7
Regulating the regulators via targeting CD38 in the tumor microenvironment
Dutta, N., Halder, N., Chini, E. N., Kim, S., & Manna, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1745988 · Cited by 7
CTLA-4-Ig internalizes CD80 in fibroblast-like synoviocytes from chronic inflammatory arthritis mouse model
Miura, Y., Isogai, S., Maeda, S., & Kanazawa, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-20694-7 · Cited by 7
Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors
Miller, C. L., Sagiv-Barfi, I., Neuhöfer, P., Czerwinski, D. K., Bertozzi, C. R., Cochran, J. R., & Levy, R. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200950 · Cited by 7
FOXP3: A Player of Immunogenetic Architecture in Lung Cancer
Ziółkowska‐Suchanek, I., & Żurawek, M. (2024) · Genes · doi:10.3390/genes15040493 · Cited by 8
“It was shown that CTLA-4 is constitutively expressed on Treg cells [44].”
Background
New expression of PD-L1 on activated CD4+ T cells opens up new opportunities for cell interactions and signaling
Mazerolles, F. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.110831 · Cited by 8
Using PD-L1 full-length structure, enhanced induced fit docking and molecular dynamics simulations for structural insights into inhibition of PD-1/PD-L1 interaction by small-molecule ligands
Urban, V. A., Nazarenko, P. N. P., Перепечко, С. А., & Veresov, V. G. (2022) · Molecular Simulation · doi:10.1080/08927022.2022.2080824 · Cited by 8
“In accordance with a recent paper by Sakaguchi et al [75], PD-L1 from the cis PD-L1/CD80 complex can be suggested as a monomer competent for binding to PD-1, after the trogocytosis of CD80 by CTLA-4.”
Result
Prognostic Profiling of the EMT-Associated and Immunity-Related LncRNAs in Lung Squamous Cell Carcinomas
Sun, Q., Gao, Y., Zhang, Y., Cao, H., Liu, J., Neo, S., Chen, K., Bi, Y., & Wu, J. (2022) · Cells · doi:10.3390/cells11182881 · Cited by 7
“In both the TCGA and GEO datasets, some of the highly expressed immune checkpoints included CD244, HAVCR2, CD47, CD80, CTLA4, PDCD1, ICOS and IDO1 (Figure 6A,B).”
BackgroundInfluential
[Retracted] GNAI2 Is a Risk Factor for Gastric Cancer: Study of Tumor Microenvironment (TME) and Establishment of Immune Risk Score (IRS)
Yu, H., Liu, S., Wu, Z., & Gao, F. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1254367 · Cited by 7
“Downregulation of CD86 expressed on the cell membrane cannot effectively induce the activation of T cells, leading to tumor immune escape [26].”
Retracted
Breaking Immunosuppressive Barriers by Engineered Nanoplatforms for Turning Cold Tumor to Hot
Dong, J., Huang, Y., Zhou, Z., & Sun, M. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200020 · Cited by 7
Tumor-infiltrating regulatory T cell: A promising therapeutic target in tumor microenvironment
Huang, T., Li, F., Wang, Y., Gu, J., & Lü, L. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003450 · Cited by 7
Self-assembly driven nano-salinomycin for high-efficiency cancer immunotherapy by reticulum stress mediated stemness suppression
Wang, L., Cheng, W., Qin, S., Tian, H., Liu, G., Miao, P., Huang, C., Wang, H., & Jing, J. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123632 · Cited by 6
News from the T cell trogocytosis front
Barbera, S., Dimberg, A., & Essand, M. (2025) · Trends in Immunology · doi:10.1016/j.it.2025.07.008 · Cited by 7
Oral antigen exposure under costimulation blockade induces Treg cells to establish immune tolerance
Arai, M., Kawakami, R., Nakamura, Y., Naito, Y., Motooka, D., Sugimoto, A., Kimoto, T., Ohkura, N., Mikami, N., & Sakaguchi, S. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20251635 · Cited by 6
“In addition to the role of CD80/CD86 for Treg induction by APCs, it has been shown that PD-L1 + DCs are potent in inducing antigen-specific Treg cells and that PD-L1 blockade inhibits the induction (Wang et al., 2008; Francisco et al., 2009).”
InfluentialSelf-citation
Targeting the chemokine-Treg axes in tumor immune evasion: from mechanisms to therapeutic opportunities
Lian, C., Liu, L., & Zhang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1779388 · Cited by 6
“Through engagement of CTLA − 4, Tregs downregulate CD80/CD86 on antigen-presenting cells, attenuating costimulatory signaling and T cell priming (34).”
Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions
Nagaraju, G. P., Nellipudi, H. R., Ganji, C., Kuppala, V., Ganji, S. P., Kumari, S., Farran, B., Srilatha, M., Guenter, R. E., & El‐Rayes, B. F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02705-5 · Cited by 7
“133 This can competitively inhibit B7 binding to CD28 receptors, thereby inhibiting T cell activation and promoting immune suppression in PDAC.”
Receptor transfer between immune cells by autoantibody-enhanced, CD32-driven trogocytosis is hijacked by HIV-1 to infect resting CD4 T cells
Albanese, M., Chen, H., Gapp, M., Muenchhoff, M., Yang, H.-H., Peterhoff, D., Hoffmann, K., Xiao, Q., Ruhle, A., Ambiel, I., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101483 · Cited by 7
“In 75–78 In contrast to CAR-based immunotherapies, in which adverse effects due to trogocytosis are triggered by Fc-mediated antibody binding to the acceptor cells, the process we describe elicits anti-body-mediated trogocytosis upon binding to the Fc g R on the donor cell.”
Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis
Li, V., Binder, M. D., Purcell, A. W., & Kilpatrick, T. J. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578347 · Cited by 7
Future investigative directions for novel therapeutic targets in head and neck cancer
Nguyen, J. P., Woerner, L. C., Johnson, D. E., & Grandis, J. R. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2417038 · Cited by 6
“In addition, CTLA-4 binding to CD80 on antigen presenting cells induces transendocytosis where the CTLA-4/CD80 complex internalizes and reduces CD80 signaling [90].”
A better understanding of the role of the CTLA–CD80/86 axis in the treatment of autoimmune diseases
Darvish, Z., Kheder, R. K., Faraj, T. A., Najmaldin, S. K., Mollazadeh, S., Nosratabadi, R., & Esmaeili, S. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3895 · Cited by 6
“27 Finally, it should bring to light that CTLA4 dysfunctions have been related with autoimmunity.”
Background
The Biological Significance of Trogocytosis
Agbakwuru, D., & Wetzel, S. A. (2024) · Results and problems in cell differentiation · doi:10.1007/978-3-031-62036-2_5 · Cited by 6
MicroRNA-98-5p Inhibits IFI44L-Mediated Differentiation of Dendritic Cells and Activation of Interferon Pathway in Systemic Lupus Erythematosus
Huang, X., Tan, Y., Wu, R., Li, Q., & Luo, S. (2024) · Immunological Investigations · doi:10.1080/08820139.2023.2300346 · Cited by 5
“CD40, CD80, CD83, and CD86 are usually known as markers for mature DCs and costimulatory receptors (Shenoda & Ajit, 2016; Tekguc et al., 2021; Wardowska, 2020).”
Background
Treg cells augment self-tolerance during infection
Kawakami, R., & Sakaguchi, S. (2025) · Nature Immunology · doi:10.1038/s41590-025-02141-7 · Cited by 5
Self-citation
Immunotherapy in central nervous system tumors
Huang, Y., Liu, Y., Zeng, H., Yang, J., Li, Z., Xu, J., Jin, L., Liu, X., & Zhou, L. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002993 · Cited by 6
“Treg has been shown to express CTLA-4, which has been demonstrated to competitively bind to CD80/CD86 and to block CD28 co-stimulatory signaling [ 83 ] .”
Programmed death-ligand 1 on ex vivo-expanded toll-like-receptor-Bregs prevents allograft rejection by Breg viability promotion, CD4+ T effector cell suppression, and regulatory T cell induction
Liao, M., Liu, J. L., Lee, K. M., Tomofuji, K., Tanimine, N., Markmann, C., Deng, K., Matheson, R., Yu, M., Bourgeois, O., et al. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.08.031 · Cited by 5
Specialized Dendritic Cells Mediating Peripheral Tolerance to Intestinal Antigens
Fu, L., & Littman, D. R. (2025) · Immunological Reviews · doi:10.1111/imr.70082 · Cited by 5
Crosstalk Between Extracellular Vesicles and Regulatory T Cells Across Cancers: From Interaction to Therapeutic Potential
Liu, D., Hao, Z., He, G., & Huang, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s562593 · Cited by 5
“17 Besides CD80/CD86, CTLA-4 also removes other immune-stimulating factors.”
The Trm-Treg Axis as a tissue-encoded immune checkpoint in chronic inflammation and autoimmunity
Li, L., Xia, Y., & Liu, Y. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103977 · Cited by 7
In situ self-assembled cell reservoir hydrogel for maneuvering multistage radioimmunotherapy
Chen, Y., Chen, Q., Ma, Y., Zhang, C., Xu, J., Li, K., Sun, Y., Su, X., Wei, M., Bao, R., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68490-5 · Cited by 5
“The increased CTLA-4 expression and decreased CD8 + T/ Treg ratio would potentiate DC tolerance and prevent antigen presentation for constrained antitumor immune effects 55 .”
Regulatory T Cell Heterogeneity in the Steady State and Tumor
Kim, D., Lee, N., & Ha, S. (2026) · Immune Network · doi:10.4110/in.2026.26.e10 · Cited by 5
“CTLA-4 competes with CD28 for CD80/CD86 on antigen-presenting cells (71,72) and reduces their costimulatory capacity through trogocytosis (73).”
Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026
Poe, J., Kim, C. J. H., Coleman, C., Nguyen, H. H. M., Velazhahan, V., Bergsneider, B. H.-L., Sanker, V., Kim, S., Chen, Y. M., Abikenari, M. A., et al. (2026) · Cells · doi:10.3390/cells15060561 · Cited by 6
Programmable CAR immunotherapies for neurodegenerative proteinopathies
Pesce, G., Estivill-Alonso, M., & Ventura, S. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.02.009 · Cited by 5
Interactions Between Immunosuppressive Regimens and Cytomegalovirus Infection After Solid-Organ Transplantation
Bellier, L. M., Kaminski, H., Merville, P., & Couzi, L. (2026) · Transplant International · doi:10.3389/ti.2026.15987 · Cited by 5
“Because belatacept has a high binding affinity for CD80, it can disrupt CD80/PD-L1 heterodimers [36].”
Foxp3+ Tregs in HCC immunity and immunotherapy
Feng, M., & Granito, A. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.05.004 · Cited by 6
Non-coding RNA in tumor-infiltrating regulatory T cells formation and associated immunotherapy
Ma, Y., Xu, X., Wang, H., Liu, Y., & Piao, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1228331 · Cited by 5
Predicting the mechanism of action of YQYYJD prescription in the treatment of non-small cell lung cancer using transcriptomics analysis
Yin, Y., Wang, Y., Wang, C., Zhang, Y., Qi, A., Song, J., Xu, L., Yang, W., & Jiao, L. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117984 · Cited by 5
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
Shah, M., Hussain, M. S., & Woo, H. G. (2025) · Genomics & Informatics · doi:10.1186/s44342-024-00033-0 · Cited by 6
Physiological Oxygen Levels in the Microenvironment Program Ex Vivo-Generated Conventional Dendritic Cells Toward a Tolerogenic Phenotype
Peter, A., Vermeulen, M., Delen, M. V., Dams, A., Peeters, S., Reu, H. D., Marei, W. F. A., Berneman, Z. N., & Cools, N. (2025) · Cells · doi:10.3390/cells14100736 · Cited by 5
“T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), and CD80/CD86—cytotoxic T lymphocyte-associated protein-4 (CTLA-4) interactions, combined with secretion of anti-inflammatory cytokines (e.g., IL-10), suppress effector T cell activation and support Treg induction [21–24].”
Tregs and Platelets Play Synergistic Roles in Tumor Immune Escape and Inflammatory Diseases
Gao, H., Zhou, Y., & Chen, X. (2022) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2023047234 · Cited by 7
Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer
Lei, X., Wang, Y., Broens, C., Borst, J. G., & Xiao, Y. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.07.006 · Cited by 5
Convergence, plasticity, and tissue residence of regulatory T cell response via TCR repertoire prism
Nakonechnaya, T. O., Moltedo, B., Putintseva, E. V., Leyn, S., Bolotin, D. A., Britanova, O. V., Shugay, M., & Chudakov, D. M. (2024) · eLife · doi:10.7554/elife.89382.3 · Cited by 5
Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review
Tom, V. V., José, A. D. L. F. H., Mallick, S., Sasidharan, A., Pawar, R., Somayaji, Y., & Fernandes, R. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03985-4 · Cited by 5
“Biomarkers like CD8 + TIL density and IFN-γ levels are being studied to enhance patient stratification for these therapies (Tekguc et al. 2021).”
Convergence, plasticity, and tissue residence of regulatory T cell response via TCR repertoire prism
Nakonechnaya, T. O., Moltedo, B., Putintseva, E. V., Leyn, S., Bolotin, D. A., Britanova, O. V., Shugay, M., & Chudakov, D. M. (2023) · eLife · doi:10.7554/elife.89382 · Cited by 7
The Therapeutic Potential of Farm Dust Extracts in a Mouse Model of Eosinophilic Inflammation
Korkmaz, R. Ü., Omony, J., Tan, X., Klotz, M., Dragunas, G., Chen, S., Shankhwar, S., Ertüz, Z., Müller, C., Ragab, M., et al. (2026) · Allergy · doi:10.1111/all.70121 · Cited by 4
Initial or continuous coculture with umbilical cord-derived mesenchymal stromal cells facilitates in vitro expansion of human regulatory T-cell subpopulations
Ou, Q., Cormican, S., Power, R., Hontz, S., Hanley, S. A., Islam, M. N., Shaw, G., Deedigan, L., Horan, E., Elliman, S. J., et al. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf012 · Cited by 5
“26 Furthermore, the mechanistic underpinnings of the differential impact of hUC-MSCs on naive and non-naive Treg subpopulations are of fundamental interest for future investigation.”
Loss of PI3Kδ Activity Drives Autoimmune Colitis by Impairing Extrathymic Treg Differentiation
Lim, E. L., Qian, Y., Sugihara, F., Tanaka, A., & Sakaguchi, S. (2025) · European Journal of Immunology · doi:10.1002/eji.70069 · Cited by 5
“Tregs (CD4 + CD25 + GITR + DAPI − ) were sorted from the spleen and LN (after B cell depletion) of WT and PI3K δ D910A mice, and cocultured overnight with JAWS immortalized dendritic cells expressing GFP or fusion constructs of CD80-GFP and CD86-GFP [38].”
Self-citation
Malignant cell-mediated Treg immune suppression via ICOSLG-ICOS axis in tumor microenvironment relates to nasopharyngeal carcinoma prognosis
Tan, Y., Zhou, J., Liu, K., Wu, Z., Liu, R., Zhou, J., Li, Y., Zhao, Y., Ma, X., Zhou, G., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115743 · Cited by 4
Immunotherapeutic Strategies Based on CAR-T Cells in Hepatocellular Carcinoma
Hemmati, N. (2025) · EMJ Oncology · doi:10.33590/emjoncol/tabt3057 · Cited by 4
From Cell Death and Activation to Paralysis: Dysregulated Conventional Dendritic Cells in SIRS , Sepsis and Major Trauma Promote Immunosuppression
Ashayeripanah, M., Roquilly, A., & Villadangos, J. A. (2026) · Immunological Reviews · doi:10.1111/imr.70087 · Cited by 6
“In a mutually reinforcing loop, Tregs promote cDC toleroge-nicity through contact dependent inhibitory receptors such as CTLA-4::CD80/CD86 [126, 127], and LAG3::MHC-II [128] as well as via soluble mediators including IL-10 [127] and IDO [105].”
Next generation CAR-T cells to tackle solid tumors
Abreu, T. R., Godinho‐Santos, A., Amaral, A. T., Paiva, A. A., Moreira, J. N., & Gonçalves, J. R. M. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114650 · Cited by 5
Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
Jové, M., Braña, I., Oliva, M., Hernando‐Calvo, A., Erasun, C., Mato-Berciano, A., Maliandi, M. V., Torres-Manjon, S., Rojas, L. A., Connelly, S., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0601 · Cited by 4
Astragalus root increases Treg and Th17 involvement in embryo implantation and pregnancy maintenance by decreasing CTLA-4+ Tregs
Kobayashi, K., & Sasaki, K. (2024) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2023.01100 · Cited by 4
“CTLA-4 expressed on Tregs has the ability to strip off MHC-Ⅱ and the costimulatory molecule B7 from APCs and express B7 on the surface of CTLA-4 + Tregs, resulting in impaired antigen-presenting activity of APCs ( 28 ).”
Background
Single-cell analysis of nasal epithelial cell development in domestic pigs
Wang, W., Liu, R., Zhong, Q., Cao, Y., Qi, J., Li, Y., & Yang, Q. (2024) · Veterinary Research · doi:10.1186/s13567-024-01403-w · Cited by 4
“In brief, dendritic cells and macrophages exhibit increased expression of CD80, CD86, CD163 and HLA-DRA [38–40].”
Background
Gaps in maternal-fetal interface rejection response: chronic histiocytic intervillositis
Zhang, X., Fang, Z., & Wang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1625701 · Cited by 4
Modeling the interaction between donor-derived regulatory T cells and effector T cells early after allogeneic hematopoietic stem cell transplantation
Nishiyama, N., Ruoff, P., Jiménez, J. C., Miwakeichi, F., Nishiyama, Y., & Yata, T. (2023) · Biosystems · doi:10.1016/j.biosystems.2023.104889 · Cited by 4
A pan-cancer analysis of the MAPK family gene and their association with prognosis, tumor microenvironment, and therapeutic targets
Qin, Y., Yang, Y., Ren, Y.-H., Gao, F., Wang, M., Li, G., Liu, Y., & Fan, L. (2023) · Medicine · doi:10.1097/md.0000000000035829 · Cited by 5
A Systematic Review of the Advances in the Study of T Lymphocyte Suppressor Receptors in HBV Infection: Potential Therapeutic Targets
Zhou, D., Liu, L., Liu, J., Li, H., Zhang, J., & Cao, Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051210 · Cited by 4
“Concurrently, it stimulates the release of free PD-L1 from APCs, exerting a dual inhibitory influence on T cell immune responses [23].”
Background
HLA-DRB5 Overexpression Promotes Platelet Reduction in Immune Thrombocytopenia Mice Model by Facilitating MHC-II-Mediated Antigen Presentation
Ren, Y., Ying, Q., Chen, Y., Liao, C., Li, A., & Ye, Q. (2024) · Acta Haematologica · doi:10.1159/000538749 · Cited by 4
“A reduction in CD80/CD86 expression on APCs inhibits the immune responses of T cells [48].”
Umbilical Cord Mesenchymal Stem Cell Secretome: A Potential Regulator of B Cells in Systemic Lupus Erythematosus
Yordanova, A., Ivanova, M. G., Tumangelova-Yuzeir, K. D., Angelov, A. K., Kyurkchiev, S., Belemezova, K., Kurteva, E. K., Kyurkchiev, D. S., & Ivanova‐Todorova, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312515 · Cited by 4
Combining radiation with immune checkpoint inhibitors therapy for HCC: From the alteration of the immune microenvironment by radiotherapy
Zhou, K., Jiang, Y., Feng, S., Wang, T.-Y., Wang, L., Cao, J., & Jiao, Y. (2022) · Radiation Medicine and Protection · doi:10.1016/j.radmp.2022.07.005 · Cited by 4
A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with Verteporfin
Liang, J., Fang, D., Gumin, J., Najem, H., Sooreshjani, M., Song, R., Sabbagh, A., Kong, L., Duffy, J. T., Balyasnikova, I. V., et al. (2023) · Cancers · doi:10.3390/cancers15041085 · Cited by 4
CTLA4 prohibits T cells from cross-dressing
Paillon, N., & Hivroz, C. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230419 · Cited by 4
Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma
Kgokolo, M., Malinga, N. Z., Steel, H. C., Meyer, P. W. A., Smit, T., Anderson, R., & Rapoport, B. L. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101867 · Cited by 4
Cardiovascular Disease Risk Factors, Immune Checkpoints and Tregs
Shao, Y., Saaoud, F., Xu, K., Lu, Y., Jiang, X., Wang, H., & Yang, X. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-62806-1_2 · Cited by 4
Expression Pattern and Prognostic Value of CTLA-4, CD86, and Tumor-Infiltrating Lymphocytes in Rectal Cancer after Neoadjuvant Chemo(radio)therapy
Yin, X., Wang, C., Feng, L., Bai, S.-M., Feng, W., Ouyang, N., Chu, Z., Fan, X., & Qin, Q. (2022) · Cancers · doi:10.3390/cancers14225573 · Cited by 4
“On the contrary, in vivo experiments have verified that CTLA-4 can deplete CD80 and CD86 via trogocytosis [17].”
Background
Activated CD4+ T cells upregulate PD-L1 expression on B cells through CD40/CD40L signaling and direct contact in systemic lupus erythematosus
Lai, S., Li, N., Chen, S., Wang, Y., Hong, D., Xu, W., Chen, Z., Li, B., & Xie, C. (2025) · Clinical Immunology · doi:10.1016/j.clim.2025.110535 · Cited by 3

Authors: Tekguc, M., Wing, J. B., Osaki, M., Long, J., & Sakaguchi, S.
Affiliations: Laboratory of Experimental Immunology, World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, Suita 565-0871, Japan;
Immunology Frontier Research Center, The University of Osaka (JP)
Kyoto University (JP)
Corresponding author: Sakaguchi, Shimon
ORCID: Tekguc, Murat
Wing, James Badger
Osaki, Motonao
Long, Jia
Sakaguchi, Shimon
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2021-07-23
Volume: 118
Issue: 30
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.2023739118
PMC: PMC8325248
OpenAlex: W3185714107
Cited by: 490
References: 53
Citations by year: 2026: 116 · 2025: 123 · 2024: 114 · 2023: 72 · 2022: 61 · 2021: 4
FWCI: 23.46
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.pnas.org/site/aboutpnas/licenses.xhtml (vor, 184 d)
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
OUKA (Osaka University Knowledge Archive) (Osaka University) (submittedVersion)
Funders: MEXT | Japan Society for the Promotion of Science (16H06295, 18K07175)
MEXT | JST | Core Research for Evolutional Science and Technology (JP 19gm0010005)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: regulatory T cells, CTLA-4, trogocytosis, CD80, CD86, PD-L1, antigen-presenting cells, immune checkpoint, cancer immunotherapy
MeSH terms: Trogocytosis, Animals, Antigen-Presenting Cells, Dendritic Cells, Female, Lymphocyte Activation, Mice, Inbred BALB C, Mice, Inbred C57BL, B7-1 Antigen, Mice, Knockout, T-Lymphocytes, Regulatory, Mice, B7-2 Antigen, B7-H1 Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks